PT-141
Melanocortin receptor agonist for sexual function and libido research.
Key Benefits
acts on hypothalamic melanocortin receptors, not vascular system
bremelanotide approved for HSDD in women
demonstrated in both male and female research subjects
effects within 45–60 minutes of administration
Active Signaling Pathway
Investigated Pathways
Proposed Mechanism
PT-141 activates melanocortin receptors MC3R and MC4R in the hypothalamus, triggering dopaminergic pathways associated with sexual motivation and arousal. This central mechanism is independent of vascular effects, making it effective in subjects where PDE5 inhibitors fail.
Research Highlights
- FDA-approved as Vyleesi (bremelanotide) for hypoactive sexual desire disorder in premenopausal women
- Demonstrated significant improvement in sexual desire scores in Phase 3 trials
- Effective in both male and female subjects via central CNS mechanism
- Onset within 45–60 minutes; duration 6–12 hours
Evidence is primarily from in vitro cell studies and animal models. Human data is limited or absent.
For research use only — not for human consumption. No treatment claims.
Full Research Hub →Recommended Stacks
PT-141 is a key compound in these curated research stacks. Pair it with synergistic peptides for enhanced outcomes.
Hormonal Vitality Stack
HPG axis activation + melanocortin optimization — the complete vitality and libido research protocol.
How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 10mg vial — and when to plan your next order.
Vial supply estimate is based on standard research protocol volumes. Actual duration will vary based on your specific protocol design.
Scientific Background
Mechanism of Action
PT-141 activates melanocortin receptors MC3R and MC4R in the hypothalamus, triggering dopaminergic pathways associated with sexual motivation and arousal. This central mechanism is independent of vascular effects, making it effective in subjects where PDE5 inhibitors fail.
Clinical Context
PT-141 is the only FDA-approved peptide for sexual dysfunction that works centrally. Its mechanism through melanocortin receptors makes it complementary to vascular approaches.
Research Highlights
- FDA-approved as Vyleesi (bremelanotide) for hypoactive sexual desire disorder in premenopausal women
- Demonstrated significant improvement in sexual desire scores in Phase 3 trials
- Effective in both male and female subjects via central CNS mechanism
- Onset within 45–60 minutes; duration 6–12 hours
Storage & Reconstitution
Store at -20°C. Reconstitute with 2 mL bacteriostatic water → 5 mg/mL. Stable 4 weeks at 2–8°C.
Key Studies
Bremelanotide (PT-141) for female sexual dysfunction
Diamond LE et al.
PT-141 significantly improved sexual desire and arousal scores in women with female sexual dysfunction in Phase 2 trials.
PubMed →PT-141 for male erectile dysfunction
Rosen RC et al.
PT-141 produced significant improvement in erectile function via central CNS mechanism in men with erectile dysfunction.
PubMed →Bremelanotide for hypoactive sexual desire disorder (FDA approval basis)
Clayton AH et al.
Phase 3 trials confirmed bremelanotide's efficacy for HSDD in premenopausal women, leading to FDA approval as Vyleesi.
PubMed →Pharmacokinetics
Bioavailability indicates how much of the compound reaches systemic circulation. Peak plasma is when blood levels are highest. Half-life determines dosing frequency — compounds with short half-lives require more frequent dosing to maintain therapeutic levels.
The volume of distribution reflects how widely the compound distributes into tissues. A higher Vd means the compound concentrates in tissues rather than staying in plasma.
Receptor Binding Profile
Activates hypothalamic dopaminergic pathways for sexual arousal and motivation
Energy homeostasis and secondary sexual function effects
Central arousal mechanism independent of vascular effects
Peripheral sexual response coordination
Side Effects & Adverse Events
- Nausea (40%)
- Flushing (20%)
- Injection site reactions
- Transient blood pressure increase
- Headache
- Vomiting
- Fatigue
- Transient hypertension (monitor BP post-injection)
- Hyperpigmentation with chronic use
Contraindications & Interactions
Synergistic Compounds
Kisspeptin optimizes the HPG axis (testosterone/estrogen) while PT-141 provides direct central arousal — comprehensive sexual function support.
Kisspeptin-10 50 mcg SubQ daily + PT-141 1 mg SubQ as needed (45–60 min before).
View Compound →Transparent Global Sourcing
Manufactured
Sourced through our manufacturing partner in China
Independent Testing
Analytical reports available from Janoshik Analytical
Batch Verification
Batch-specific COAs with online verification via janoshik.com
US Fulfillment
Orders fulfilled from the United States